Gujarat Themis placed on rating watch; acquisitions cost 10x net worth
CARE flagged that Gujarat Themis's planned acquisitions are ten times its tangible net worth and funding is uncertain. The company protests, but the rating action signals a possible downgrade.
— 5 earlier stories on Gujarat Themis Biosyn Ltd. →What's new
- CARE Ratings placed Gujarat Themis's bank facilities on Rating Watch Negative.
- Concern stems from acquisitions that cost roughly ten times the company's tangible net worth.
- Company formally protested the rating action, arguing acquisitions are earnings-accretive.
Why this matters
A rating watch with negative implications means the agency sees a credible chance of downgrade. For a company that has maintained investment-grade ratings, this is a new source of uncertainty and could raise borrowing costs precisely when it needs debt to finance a giant deal. The company's protest signals confidence, but the watch shifts the burden onto management to show it can finance the acquisitions without straining its balance sheet.
What we're watching
- Funding mix for the acquisitions: QIP size and debt component.
- Whether the QIP dilutes the promoter stake further given the indirect encumbrance.
- Any response from the company detailing how it plans to address the rating agency's concerns.
The full read
The combined cost is roughly 10x its tangible net worth. That is a lot. CARE Ratings has responded by placing its bank facilities on Rating Watch with Negative Implications, concerned about funding mix and the indirect encumbrance of the promoter's 47% stake. The company filed a formal protest, arguing that the acquisitions will be earnings-accretive and that liquidity buffers and contracted cash flows should have counted. That argument may be right in the long run, but the watch changes the near-term calculus. A downgrade from investment grade would raise borrowing costs right when the company needs cheap debt. For now, the watch is a warning shot. The next move is management's: show a credible funding plan or face a rating cut.
Questions answered
- What triggered the rating watch negative?
- CARE Ratings cited the planned acquisitions of MicroBiopharm Japan for ¥21.5B and Sanofi's anti-TB portfolio for €158M, which together are roughly 10x tangible net worth, along with funding uncertainty and indirect promoter stake encumbrance.
- How big are the acquisitions relative to the company's net worth?
- The combined acquisition cost is about ten times Gujarat Themis's tangible net worth, making it a very large bet relative to its equity base.
- Is the promoter stake at risk?
- The promoter's 47% stake is indirectly encumbered via pledge and non-disposal undertaking, which CARE flagged as a concern. The rating action does not change this, but increased leverage could raise pressure.
- Why did the company protest the rating action?
- Gujarat Themis argued that the acquisitions will be earnings-accretive and that the rating decision fails to account for its liquidity buffers and contracted cash flows. It also believes the funding plan, including a ₹1,000 crore QIP, is adequate.
- What is the likely outcome of the watch?
- CARE may downgrade if the company fails to secure a credible funding plan or if debt levels rise significantly. However, the rating remains investment grade for now, and a resolution is expected within a few months.
- How does this affect the stock?
- The rating watch introduces credit uncertainty, which could modestly influence the stock. The company's protest signals confidence, but the watch is a new negative signal.
Gujarat Themis Biosyn Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on GUJTHEM →- 17 Jul 2026 · 5:18 PM IST Gujarat Themis placed on rating watch; acquisitions cost 10x net worth
- 22d ago Gujarat Themis promoter stake is now tied to third-party debt
- 48d ago Gujarat Themis will dilute a fifth of itself for a ¥21.5bn Japan deal
- 51d ago Gujarat Themis Biosyn to raise equity for ¥21.5 bn Japan deal
- 60d ago Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.